Fw: Malignant pleural mesothelioma: Computed tomography and correlation with histology.

----- Forwarded Message ----
From: HubMed - mesothelioma <rssfwd@rssfwd.com>
To: shell8377@yahoo.com
Sent: Wednesday, March 26, 2008 2:22:39 PM
Subject: Malignant pleural mesothelioma: Computed tomography and correlation with histology..

[1]Eur J Radiol. 2008 Mar 20;
Seely JM, Nguyen ET, Churg AM, Müller NL

OBJECTIVE: To review the computed tomography (CT) imaging findings of pleural mesothelioma at presentation and to correlate the CT with the histological subtype. MATERIALS AND METHODS: Pathology reports from 1997 to 2006 were reviewed at two academic institutions to identify patients with proven pleural mesothelioma. Diagnosis was based on histologic findings in specimens obtained by transthoracic needle biopsy, surgical biopsy or resection. All histology slides were reviewed by a lung pathologist. CT scans, available in 92 patients, were reviewed blindly and in random order by two independent radiologists. Kappa analysis was completed to assess inter-observer agreement. Eighty patients in whom there was no significant delay between CT imaging and histological diagnosis were assessed by logistic regression analysis to correlate CT and histologic findings. RESULTS: Seventy-two of the 92 mesotheliomas were epithelial, 15 sarcomatous, and 5 of mixed histology. All patients (77 male, 15 female, mean age 68 years) had pleural thickening on CT; the thickening was nodular in 79 patients (86%) and mediastinal in 87 (95%). Ipsilateral volume loss was seen in 42 patients (46%). Pleural effusions were present in 80 patients (87%), being large (>2/3 hemithorax) in 19 patients (21%). Atypical features at presentation included bilateral disease in three patients (3%), and spontaneous pneumothoraces in nine patients (10%). Internal mammary lymphadenopathy was observed in 48 patients (52%) and cardiophrenic lymphadenopathy in 42 (46%). Inter-observer agreement was excellent (average kappa=0.89). Ipsilateral volume loss was associated with sarcomatous or mixed mesothelioma (p=0.004). Using logistic regression analysis, other CT findings did not correlate with histological subtype. CONCLUSIONS: Ipsilateral volume loss is most frequently associated with sarcomatous or mixed mesothelioma. The remaining imaging findings are not helpful in predicting the histological subtype of malignant mesothelioma.



___
Source: http://www.hubmed.org/display.cgi?uids=18359180
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fw: New Weblog (''Blog''), MyMeso.org, Aims to Raise Awareness of Deadly Form of Lung Cancer

----- Forwarded Message ----
From: Search for mesothelioma diagnosis <rssfwd@rssfwd.com>
To: shell8377@yahoo.com
Sent: Wednesday, March 26, 2008 2:22:36 PM
Subject: New Weblog (''Blog''), MyMeso.org, Aims to Raise Awareness of Deadly Form of Lung Cancer

MONTGOMERY, Ala., BUSINESS WIRE -- Current statistics show 2,000-3,000 people are diagnosed with malignant pleural mesothelioma in the U.S. each year, and 10,000 Americans die from all asbestos-related ...

Wed, 26 Mar 2008 09:20:26 GMT

___
Source: http://digitalproducer.digitalmedianet.com/articles/viewarticle.jsp?id=342402
--
 Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc

 

Fwd: Insulin receptor substrate 1 modulates the transcriptional activity and the stability of androgen receptor in breast cancer cells.

---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Thu, Jun 5, 2008 at 1:34 AM
Subject: Insulin receptor substrate 1 modulates the transcriptional activity and the stability of androgen receptor in breast cancer cells.
To: mesothelioma77@gmail.com


[1]Breast Cancer Res Treat. 2008 Jun 4;
Lanzino M, Garofalo C, Morelli C, Le Pera M, Casaburi I, McPhaul MJ, Surmacz E, Andò S, Sisci D

Breast cancer development and progression is regulated by growth factors and steroid hormones. Although the majority of human breast cancers expresses androgen receptor (AR), the role of androgens in breast tumorigenesis remains largely unexplored. Here we demonstrate that an AR ligand, 5-alpha-dihydrotestosterone (DHT), inhibits MCF-7 breast cancer cell growth induced by insulin like growth factor 1 (IGF-I). Our results show that DHT induces association of AR with IRS-1, the major IGF-1 receptor signaling molecule. The AR/IRS-1 complex translocates to the nucleus and is recruited to gene promoters containing androgen responsive elements causing an increase of AR transcriptional activity. Moreover, IRS-1 knockdown suggests that IRS-1/AR interaction decreases the ubiquitin/proteasome dependent degradation of AR, increasing its stability. Taken together, these data indicate that nuclear IRS-1 is a novel AR regulator required to sustain AR activity and demonstrate, for the first time in breast cancer cells, the existence of a functional interplay between the IGF system and AR. This interplay may represent the molecular basis of mechanisms through which androgens exert their inhibitory role on the proliferation of breast cancer cells.



___
Source: http://www.hubmed.org/display.cgi?uids=18521741
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: The first functional study of MLH3 mutations found in cancer patients.

---------- Forwarded message ----------
From: HubMed - cancer <rssfwd@rssfwd.com>
Date: Thu, Jun 5, 2008 at 1:34 AM
Subject: The first functional study of MLH3 mutations found in cancer patients.
To: mesothelioma77@gmail.com


[1]Genes Chromosomes Cancer. 2008 Jun 2;
Korhonen MK, Vuorenmaa E, Nyström M

The MLH3 gene is one of the five mismatch repair (MMR) genes associated with hereditary nonpolyposis colorectal cancer (HNPCC). Eighteen different inherited MLH3 mutations have been reported as pathogenic in an international mutation database. In several cases, a mutation was found in a patient without a family history suggestive of inherited cancer susceptibility. In some cases, a similar mutation was also found in sporadic patients and/or healthy controls. Four patients carried an MLH3 mutation together with another inherited MMR gene variation. No functional analyses have been performed to assess the pathogenicity of these 18 mutations. MLH3 has been assumed to be less important in MMR than the other HNPCC susceptibility genes MSH2, MSH6, MLH1, and PMS2, and accordingly a low-risk gene for colorectal cancer (CRC). To assess the significance of the inherited sequence variations in MLH3, we functionally characterized seven missense mutations (Q24E, R647C, S817G, G933C, W1276R, A1394T, E1451K) scattered throughout the MLH3 polypeptide. The mutations were found in CRC or endometrial cancer patients and reported as pathogenic. Our study showed that the seven mutated MLH3 proteins, in complex with their counterpart MLH1 (MutLgamma), repaired mismatches as the wild type MutLgamma but worse than a heterodimer of MLH1 and PMS2 (MutLalpha). The results confirm that MutLgamma is a less efficient MMR complex than MutLalpha and show that the MLH3 mutations alone do not interfere with MMR. Further studies are needed to evaluate the pathogenicity of MLH3 mutations in compound with other MMR mutations. (c) 2008 Wiley-Liss, Inc.



___
Source: http://www.hubmed.org/display.cgi?uids=18521850
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Acute lymphoblastic leukemia and Down syndrome: presenting features and treatment outcome in the experience of the Italian Association of Pediatric Hematology and Oncology (AIEOP).

---------- Forwarded message ----------
From: HubMed - cancer <rssfwd@rssfwd.com>
Date: Thu, Jun 5, 2008 at 1:34 AM
Subject: Acute lymphoblastic leukemia and Down syndrome: presenting features and treatment outcome in the experience of the Italian Association of Pediatric Hematology and Oncology (AIEOP).
To: mesothelioma77@gmail.com


[1]Cancer. 2008 Jun 2;
Arico M, Ziino O, Valsecchi MG, Cazzaniga G, Baronci C, Messina C, Pession A, Santoro N, Basso G, Conter V,

BACKGROUND.: The presenting features and treatment outcome of 120 patients with Down syndrome (DS) and childhood acute lymphoblastic leukemia (ALL) were compared with 6237 non-DS patients treated in the same years. METHODS.: We reviewed the database of 6 consecutive Italian Association of Pediatric Hematology and Oncology (AIEOP)-ALL trials conducted between 1982 and 2004. Features of DS patients were compared with those of non-DS patients. RESULTS.: The 120 DS patients (1.9%) were more often girls (P = .027), aged >/=10 years (P = .014), and high risk according to National Cancer Institute (NCI) criteria (P = .045). The distribution of white blood cell count did not differ (P = .32). DS patients belonged less frequently to the current high-risk group (P = .017). In all but 1 case they demonstrated B-cell precursor (BCP) immunophenotype (P

___
Source: http://www.hubmed.org/display.cgi?uids=18521927
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Predicting complications following expander/implant breast reconstruction: an outcomes analysis based on preoperative clinical risk.

---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Thu, Jun 5, 2008 at 1:34 AM
Subject: Predicting complications following expander/implant breast reconstruction: an outcomes analysis based on preoperative clinical risk.
To: mesothelioma77@gmail.com


[1]Plast Reconstr Surg. 2008 Jun; 121(6): 1886-92
McCarthy CM, Mehrara BJ, Riedel E, Davidge K, Hinson A, Disa JJ, Cordeiro PG, Pusic AL

BACKGROUND: Complications following postmastectomy reconstruction can cause significant morbidity. The compound effect of individual risk factors on the development of complications following expander/implant reconstruction has not, however, been well delineated. This study evaluated the impact of clinical risk factors to predict complications following postmastectomy expander/implant reconstruction. METHODS: From 2003 through 2004, 1170 expander/implant reconstructions were performed at a single center. A prospectively maintained database was reviewed. Variables including age, smoking status, body mass index, history of diabetes, hypertension, chemotherapy and/or radiation, as well as timing and laterality of reconstruction were evaluated. The primary endpoint was the development of a complication; the secondary endpoint was failure of reconstruction. RESULTS: Over the 2 year study period, 1170 expander/implant reconstructions were performed in 884 patients. The odds of developing complications was 2.2 times greater in smokers (p

___
Source: http://www.hubmed.org/display.cgi?uids=18520873
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Chest CT of Incidental Breast Lesions.

---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Thu, Jun 5, 2008 at 1:34 AM
Subject: Chest CT of Incidental Breast Lesions.
To: mesothelioma77@gmail.com


[1]J Thorac Imaging. 2008 May; 23(2): 148-155
Yi JG, Kim SJ, Marom EM, Park JH, Jung SI, Lee MW

Chest computed tomography (CT) is routinely used for the evaluation of diseases of the chest involving the lung, mediastinum, pleura, chest wall, and diaphragm. Benign and malignant breast lesions are not uncommonly encountered incidentally on chest CT. The chest CT radiologist should be aware of the different breast pathologies and their CT appearances as some can be diagnosed by chest CT, whereas others, such as breast cancer, should not be overlooked. The purpose of this pictorial essay is to show various common and uncommon breast conditions encountered while interpreting chest CT scans in our daily practice.



___
Source: http://www.hubmed.org/display.cgi?uids=18520577
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Systemic chemokine levels in breast cancer patients and their relationship with circulating menstrual hormones.

---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Thu, Jun 5, 2008 at 1:34 AM
Subject: Systemic chemokine levels in breast cancer patients and their relationship with circulating menstrual hormones.
To: mesothelioma77@gmail.com


[1]Breast Cancer Res Treat. 2008 Jun 4;
Potter SM, Dwyer RM, Curran CE, Hennessy E, Harrington KA, Griffin DG, Kerin MJ

Introduction The chemokines Stromal Cell-Derived Factor-1alpha (SDF-1alpha/CXCL12) and Monocyte Chemotactic Protein-1 (MCP-1/CCL2) have been implicated in breast cancer progression. We recently reported elevated systemic MCP-1 in breast cancer patients. This study investigated circulating levels of SDF-1alpha in breast cancer patients, and addressed potential hormonal regulation of these two potent chemokines. Methods SDF-1alpha levels were determined by ELISA in 114 breast cancer patients and 85 controls, and correlated with clinical data. Blood samples were collected from 36 healthy premenopausal volunteers weekly for four weeks to measure Luteinising Hormone (LH), Follicular Stimulating Hormone (FSH), Oestradiol and Progesterone using a Bayer ADVIA((R)) Centaur Immunoassay system, in parallel with SDF-1alpha and MCP-1. CXCL12 expression was determined using RQ-PCR in primary tumour stromal cells (n = 16) harvested at surgery. Results Plasma SDF-1alpha was significantly higher in breast cancer patients than age-matched controls and had a significant correlation with tumour grade and epithelial subtype. Investigation of menstrual variations of these chemokines revealed lower SDF-1alpha levels in the mid-luteal phase of the menstrual cycle and a significant positive correlation with circulating Oestradiol. MCP-1 levels showed no correlation with menstrual hormones. There was a trend towards increased CXCL12 expression in tumour compared to normal stromal cells. Conclusions The elevated level of SDF-1alpha detected in breast cancer patients, and it's correlation with prognostic indicators, highlights the importance of this chemokine in disease progression. Elucidation of factors influencing chemokine secretion supports clarification of their role in tumourigenesis.



___
Source: http://www.hubmed.org/display.cgi?uids=18521742
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc